Results 81 to 90 of about 3,775 (204)

Efficacy of bezlotoxumab in participants receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection

, 2020
Background: In phase 3 MODIFY I/II trials, bezlotoxumab significantly reduced recurrence of Methods: In MODIFY I/II (NCT01241552/NCT01513239), participants received a single infusion of bezlotoxumab (10 mg/kg) or placebo during anti-CDI treatment.
Gerding, Dale N, Garey, Kevin W, Dorr, Mary Beth, Rahav, Galia, Dubberke, Erik R, Tipping, Robert, Kelly, Ciarán P, Mosley, Audrey   +7 more
core   +1 more source

Impact of Clostridioides difficile Infection on Clinical Outcomes in Hospitalized IBD Patients and the Role of Fecal Microbiota Transplantation: A Retrospective Cohort Study

The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 5, May 2025.
ABSTRACT Clostridioides difficile infection (CDI) worsens the prognosis of patients with inflammatory bowel disease (IBD). This retrospective cohort study aimed to evaluate the risk factors, clinical manifestations, and outcomes of CDI in hospitalized patients with IBD, including those with toxin A/B results between April 2007 and April 2021.
Puo‐Hsien Le, Chyi‐Liang Chen, Chia‐Jung Kuo, Pai‐Jui Yeh, Chien‐Chang Chen, Yi‐Ching Chen, Cheng‐Tang Chiu, Hao‐Tsai Cheng, Yung‐Kuan Tsou, Yu‐Bin Pan, Cheng‐Hsun Chiu   +10 more
wiley   +1 more source

Macrolide Allergic Reactions

Pharmacy, 2019
Macrolides are antimicrobial agents that can be used to treat a variety of infections. Allergic reactions to macrolides occur infrequently but can include minor to severe cutaneous reactions as well as systemic life-threatening reactions such as ...
Kristy M. Shaeer, Elias B. Chahine, Sheeba Varghese Gupta, Jonathan C. Cho   +3 more
doaj   +1 more source

Isolation of Fidaxomicin and Shunt Metabolites from Actinoplanes deccanensis

A protocol for the isolation of the antibiotic fidaxomicin (Fdx) from Actinoplanes deccanensis and the isolation of shunt metabolites from A. deccanensis fdxG2- is reported. We constructed the mutant strain A.
Erik, Jung, Rolf, Müller, Maja, Hunter, Alexander, Major, Andrea, Dorst, Karl, Gademann, Tatjana, Teofilovic   +6 more
core   +1 more source

Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study

Heliyon
Objectives: The main aim of this study was to compare the clinical outcomes of patients attended in our area with Clostridioides difficile infection (CDI) (sustained cure, recurrence or death) in relation to treatment to normal or hypervirulent C ...
Marcos Hernando-Gozalo, Carlos Rescalvo-Casas, Laura Seijas-Pereda, Juan Cuadros-González, Ramón Pérez-Tanoira   +4 more
doaj   +1 more source

Fidaxomicin gyártásközi- és végtermék hatóanyagtartalmának meghatározására szolgáló analitikai módszer validálása

, 2015
Fidaxomicin hatóanyagtartalmának meghatározására szolgáló HPLC-s módszert validáltam. Célom az volt, hogy a módszert a szabványműveleti előírásokban foglaltaknak megfelelően ellenőrizzem le, és bebizonyítsam, hogy a módszer biztonságosan használható ...
Drengubák, Diána
core  

Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections:a meta-analysis and indirect treatment comparison

, 2014
Objectives To evaluate the efficacy of fidaxomicin treatment, which has a limited effect on the normal gut flora, compared with vancomycin and metronidazole treatment in Clostridium difficile infections (CDIs). Methods A systematic literature review was
Cornely, Oliver A., Odufowora-Sita, Olatunji, Odeyemi, Isaac A. O., Retsa, Peny, Nathwani, Dilip, Ivanescu, Cristina   +5 more
core   +1 more source

SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment

ChemistryOpen
The emergence of drug‐resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID‐19 pandemic.
B.Sc. Sara Protić, M.Sc. Milica Crnoglavac Popović, M.Sc. Nevena Kaličanin, Dr. Olivera Prodanović, Dr. Milan Senćanski, Dr. Jelena Milićević, Dr. Kristina Stevanović, Dr. Vladimir Perović, Dr. Slobodan Paessler, Dr. Radivoje Prodanović, Dr. Sanja Glišić   +10 more
doaj   +1 more source

An Evaluation of Fidaxomicin Use in a Community Health System

, 2014
Background: Fidaxomicin is a narrow spectrum, non-absorbed antibiotic that is indicated for the treatment of Clostridium difficile infection (CDI).
Boyd, Sarah
core  

Clostridioides difficile: Modern Approaches in Pathogenesis, Diagnosis, Treatment, Prevention, Emerging Perspectives and Health Economics

Gastroenterology Insights
Introduction: Clostridioides difficile (C. difficile) is a major cause of antibiotic-associated diarrhea and healthcare-associated infections, with rising global incidence and severity due to the emergence of hypervirulent strains.
Nikoletta T. Karavasili, Konstantinos H. Katsanos, Ioanna Nefeli Mastorogianni, Maria Veatriki Christodoulou, Georgios Manomenidis, Dimitrios Kosmidis, Anastasios Tzenalis, Albani Eleni, Stavroula Tsiara, Dimitrios K. Christodoulou   +9 more
doaj   +1 more source